CASI Pharmaceuticals Discloses Material Development Relating To Its Dispute With Juventas

On April 8, 2024, CASI Pharmaceuticals, announced that, with respect to the Company's previously announced dispute with Juventas Cell Therapy Ltd., an emergency arbitrator appointed by the Hong Kong I

BenzingaApr 9 05:03

CASI Pharmaceuticals Gets Emergency Injunctive Relief in Dispute With Juventas Cell Therapy >CASI

CASI Pharmaceuticals Gets Emergency Injunctive Relief in Dispute With Juventas Cell Therapy >CASI

Dow JonesApr 9 05:02

CASI Pharmaceuticals: Order Prohibits Juventas From Commercializing CNCT19 >CASI

CASI Pharmaceuticals: Order Prohibits Juventas From Commercializing CNCT19 >CASI

Dow JonesApr 9 05:02

CASI Pharmaceuticals Wins Emergency Relief Regarding the Dispute With Juventas Cell Therapy Ltd Prohibiting Juventas From Commercializing CNCT19

On April 8, 2024, CASI Pharmaceuticals, Inc., a Cayman Islands incorporated company ("CASI" or the "Company") announced that, with respect to the Company's previously announced dispute with Juventas

BenzingaApr 8 19:34

Recap: CASI Pharmaceuticals Q4 Earnings

CASI Pharmaceuticals (NASDAQ:CASI) reported its Q4 earnings results on Thursday, March 28, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsCASI Pharmaceuticals misse

BenzingaMar 28 20:20

CASI Pharmaceuticals GAAP EPS of -$2.02, Revenue of $33.88M

Seeking AlphaMar 28 19:22